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ABSTRACT
Pituitary adenylate cyclase-activating polypeptide (PACAP) rescues
dopaminergic neurons from neurodegeneration and improves motor
changes induced by 6-hydroxy-dopamine (6-OHDA) in rat parkinsonian
models. Recently, we investigated the molecular background of
the neuroprotective effect of PACAP in dopamine (DA)-based
neurodegeneration using rotenone-induced snail and 6-OHDA-induced
rat models of Parkinson’s disease. Behavioural activity, monoamine (DA
andserotonin),metabolicenzyme(S-COMT,MB-COMTandMAO-B)and
PARK7 protein concentrations were measured before and after PACAP
treatment inbothmodels. Locomotionand feedingactivityweredecreased
in rotenone-treated snails,which correspondedwell to findingsobtained in
6-OHDA-induced rat experiments. PACAP was able to prevent the
behavioural malfunctions caused by the toxins. Monoamine levels
decreased in both models and the decreased DA level induced by
toxinswasattenuatedby∼50% in thePACAP-treatedanimals. In contrast,
PACAP had no effect on the decreased serotonin (5HT) levels. S-COMT
metabolic enzymewasalso reducedbut a protective effect of PACAPwas
notobserved ineitherof themodels.Following toxin treatment,asignificant
increase in MB-COMTwas observed in both models and was restored to
normal levelsbyPACAP.Adecrease inPARK7wasalsoobserved inboth
toxin-induced models; however, PACAP had a beneficial effect only on
6-OHDA-treatedanimals. Theneuroprotective effect ofPACAP indifferent
animal models of Parkinson’s disease is thus well correlated with
neurotransmitter, enzyme and protein levels. The models successfully
mimicseveral,butnotalletiologicalpropertiesof thedisease,allowingusto
study themechanismsof neurodegenerationaswell as testingnewdrugs.
The rotenone and 6-OHDA rat and snail in vivo parkinsonianmodels offer
an alternative method for investigation of the molecular mechanisms of
neuroprotective agents, including PACAP.
KEY WORDS: Rotenone, 6-OHDA, PD models, Dopamine, PARK7,
DJ-1, PACAP
INTRODUCTION
Parkinson’s disease (PD) is characterized by dopaminergic (DAergic)
neuron loss in the substantia nigra pars compacta (SNc) leading to
progressive motor disability (Damier et al., 1999). Although several
pharmacological compounds can mitigate motor and non-motor
symptoms of the disease, the applied drugs are unable to cure or
prevent it from progression (Schapira, 2005). The ideal therapy
without long-term side effects is currently not available for patients
suffering from PD; therefore, it is of the utmost importance to find or
develop new drugs that prevent neurodegeneration and illness
progression (LeWitt, 2016; Schapira et al., 2006).
Toxin-induced animal models have contributed substantially
to the elucidation of the pathogenic mechanisms and the
pathophysiology underlying PD. The most widely used
parkinsonian models are generated by 6-hydroxy-dopamine (6-
OHDA), rotenone, 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine
(MPTP), paraquat and amphetamine (Jagmag et al., 2016). These
chemicals have all been shown to be neurotoxins that induce a loss
of DAergic neurons in the SNc and ventral tegmental area (VTA) in
model animals. Neurotoxins reproduce one or more key
pathological features of clinical PD within a shorter period of
time in animals. For example, both 6-OHDA and rotenone induce
progressive DAergic neuronal degeneration by generating oxidative
stress. It is observed that 6-OHDA affects mitochondrial
translocation of the PARK7 (also known as DJ-1) chaperone
protein (Miyama et al., 2011). In addition, rotenone also affects
α-synuclein phosphorylation, inducing formation of Lewy-body-
and ubiquitin-like inclusions (Bove and Perier, 2012; Jagmag et al.,
2016; Sonia et al., 2013). Behavioural alterations and α-synuclein
inclusions, however, reveal variations underlying the limited
validity of different parkinsonian models (Bove and Perier, 2012).
Nevertheless, rotenone is highly lipophilic and easily crosses the
blood-brain barrier (BBB); therefore, it can be injected
intraperitoneally, intravenously or subcutaneously for systemic
treatment (Jagmag et al., 2016). There is only one publication where
rotenone has been unilaterally injected into the rat brain (Xiong
et al., 2009). Although rotenone induces loss of DAergic neurons,
this model is difficult to replicate owing to the high mortality rate of
the rats. The hydrophilic compound 6-OHDA (which cannot cross
the BBB) is a generally used selective toxin to induce DAergic
neuronal cell death by direct injection in the SNc or VTA in rats
(Jagmag et al., 2016).
It has been found that rotenone-induced lesions also replicate
some symptoms of PD in invertebrates (Penney and Mccabe,
2008). Chronic exposure to rotenone induces loss of tyrosine-
hydroxylase immunoreactivity in the giant DAergic neuron
(RPeD1) of the giant pond snail, suggesting that rotenone affects
the DAergic system. Decrease of brain DA content results in aReceived 22 July 2016; Accepted 6 December 2016
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progressive and irreversible decline in locomotion, feeding and
in the life span of treated snails (Vehovszky et al., 2007). The
usefulness of modelling diseases in invertebrates is often
questioned; however, physiological events at the molecular and
cellular levels established a number of similarities between
vertebrate and invertebrate PD models (Penney and Mccabe,
2008).
Since previous drugs have failed to successfully treat the disease
in clinical trials, it is suggested that multi-pathway drugs may
overcome this challenge. For that reason, we investigated the
neuroprotective effect of pituitary adenylate cyclase-activating
polypeptide (PACAP) to prevent DAergic neurons from
degeneration in the 6-OHDA-induced rat and rotenone-induced
snail parkinsonian models. PACAP belongs to the vasoactive
intestinal peptide/secretin/glucagon peptide family and it acts
through G-protein-coupled specific (PAC1-R) and unspecific
(VPAC1-R, VPAC2-R) receptors (Reglodi et al., 2015). PACAP
as neuropeptide is expressed widely in the brain of mammals at
particularly high concentrations in the hypothalamus, substantia
nigra (SN), nucleus accumbens and bed nucleus of the stria
terminalis (Bourgault et al., 2009; Ghatei et al., 1993; Palkovits
et al., 1995; Vaudry et al., 2009), as well as in different parts of the
central nervous system (CNS) of Oligochaetes, gastropods and
insects (Pirger et al., 2016). In numerous studies it has been shown
that PACAP exerts pleiotropic effects on neuronal and non-neuronal
cells, including neuroprotective effects (Reglodi et al., 2011, 2012,
2015). PACAP rescues DAergic neurons from neurodegeneration
and improves motor alterations induced by unilateral 6-OHDA or
MPTP injection in rat models of PD (Reglodi et al., 2004;
Somogyvari-Vigh and Reglodi, 2004; Takei et al., 1998; Wang
et al., 2008). Its anti-apoptotic effect has also been observed in an
invertebrate animal (Pirger et al., 2008).
Comparison of different parkinsonian models at the molecular
level may provide new information about the pathological
mechanisms of the disease and open new avenues in the
development of novel anti-neurodegenerative and neuroprotective
approaches. Our main question was whether the neuroprotective
effect of PACAP correlated with changes observed at the molecular
and system levels in the 6-OHDA and rotenone toxin models. We
investigated the effect of exogenous PACAP on the behavioural
activity (feeding and locomotion), level of monoamines [dopamine
(DA) and serotonin (5HT)], DA-metabolizing enzymes (S-COMT,
MB-COMT and MAO-B) and PARK7 protein in rat and snail
parkinsonian models in vivo. In our experiments, the widely used
hydrophilic and selective agent 6-OHDA was applied to induce
DAergic neuronal cell death in the rat model, while the highly
lipophilic compound rotenone was used in the snail model.
RESULTS
DA and 5HT quantification
Calibration curves were produced for the quantitative analysis of
DA and 5HT, using 55, 111, 556, 834 and 1112 pmol/ml DA and
122, 305, 610, 1200 and 2100 pmol/ml 5HT as external standards.
Correlation coefficients (r2) were between 0.9956 and 0.9989 for all
acceptable calibration curves both in parent ion scan (MS) and
fragment ion scan (MS/MS) modes (not shown). The limits of
detection and quantification were 2.9 and 5.8 pmol/ml for DA, and
6.2 and 9.4 pmol/ml for 5HT, respectively. Based on own exact
molecular weights and fragments, the structure of DA and 5HTwere
confirmed from rat SN and snail CNS homogenates. Quantification
was performed parallel in both MS and MS/MS modes. DA was
identified at 154.09 m/z parent ion protonated form and at
137.06 m/z fragment ion protonated form, which were
characterized by a 1.94 min retention time (Fig. 1). The 5HT was
identified at 177.10 m/z parent ion protonated form and at
160.08 m/z fragment ion protonated form, which were
characterized by a 3.89 min retention time (Fig. 2). The
identification and quantification parameters obtained from snail
CNS homogenates exactly correspond with those of rat SN,
therefore, they are not shown. The parent ion exact masses of DA
and 5HT as well as their MS/MS transitions data confirm those
described earlier (Wei et al., 2014). Based on these data,
identification of monoamines both in invertebrate and vertebrate
samples was successful.
Effect of PACAP in an invertebrate model: rotenone-induced
injury in molluscs
The neuroprotective effect of PACAP in molluscs was studied in a
rotenone-induced parkinsonian model. First, the physiological
effect of PACAP, rotenone and rotenone+PACAP together was
observed in a survival experiment (Fig. 3A). The average
percentage of surviving snails was 97.5% in the control and 90%
in the PACAP control groups. Although animals started to die from
day 3-4 in the rotenone+PACAP group compared with day 5 in the
rotenone group, snails treated with rotenone+PACAP survived
significantly longer than those treated only with rotenone.
Approximately 50% of the animals remained alive on day 12 in
the rotenone+PACAP group (Fig. 3A), whereas all animals in the
rotenone group died by day 12.
The spontaneous locomotor activity of both rotenone and
rotenone+PACAP groups significantly decreased in the
behavioural test on day 5 of treatment compared with control
animals (Fig. 3B). The snails in the rotenone group covered an
average distance of 2.0±0.5 cm in 3 min, while the control snails
covered 13.75±2.34 cm in 3 min, representing an ∼85% (P<0.001)
decrease in the locomotor activity. In contrast, the animals in the
rotenone+PACAP group covered 6.37±1.30 cm in 3 min, which is
only an ∼50% (P<0.01) decrease compared with the control group.
The locomotion test shows a significant difference between the
rotenone and the rotenone+PACAP groups (∼35%, P<0.05),
indicating that PACAP was able to prevent the severe behavioural
effect caused by rotenone in snails.
Rotenone treatment also caused a marked reduction in the feeding
rate (Fig. 3C). The number of bites made by snails in the rotenone
group on day 5 of treatment was 3.12±1.31 bites in 2 min, which is
an ∼85% (P<0.001) decrease compared with the number of bites in
control snails (22.37±1.85 bites/2 min). As in the locomotion test,
the rotenone+PACAP group showed a significantly higher rate of
feeding (13.00±1.94 bites/2 min) than snails in the rotenone group,
resulting in a 40% (P<0.001) decrease compared with the control
group (Fig. 3C).
Since monoamines are relevant in locomotor activity during cilia
movement and as they are also the main neurotransmitters in feeding
musculature, we aimed to analyse the effect of PACAP on CNS
monoamine levels. The average concentration of monoamines was
measured using HPLC-MS in the CNS of control animals. The DA
and 5HT content was found to be 3.33±0.76 and 9.87±1.87 µg/g
tissue, respectively (Fig. 4A). These data correspond well to
findings obtained earlier by HLPC-electrochemical detector (Nagy
and Hiripi, 2002). Upon rotenone treatment, the DA content of the
CNS was reduced to 55.3±12.15% (P<0.001) (normalized to
control data, see Fig. 4A). In the rotenone+PACAP group, the
decrease in the DA level was less pronounced: it decreased to 73.5±
11.5% (P<0.001) (Fig. 4B), suggesting a marked protective effect of
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PACAP in this model (P<0.05 between the rotenone and rotenone
+PACAP group). In contrast, the 5HT content decreased in both
rotenone and rotenone+PACAP groups, with no significant
difference between them. The 5HT level in the rotenone group
decreased to 64.5±9.70% (P<0.001) and in the rotenone+PACAP
group decreased to 49.9±8.60% (P<0.001) of control values
(Fig. 4C).
Next, the metabolic enzymes of DA signalling were examined in
control, rotenone and rotenone+PACAP groups by western blot
(WB). According to Sloley (2004), vertebrate-like MAO-B plays a
negligible role in metabolizing monoamines in the CNS of snails.
Therefore, we focused our experiments on the other enzyme,
COMT. The two forms, COMT soluble (S) and membrane bound
(MB), had variable expression levels in the rotenone and rotenone
+PACAP groups. Bands with a positive immune reaction were
obtained at ∼23 and 26 kDa, corresponding well to values provided
by the manufacturer (Fig. 5A). The immunopositive band of the
23 kDa S-COMT showed higher intensity in the control group
(P<0.001), while this band had very low intensity in the rotenone
and rotenone+PACAP groups (Fig. 5B). The 26 kDa band of the
MB-COMT showed an average higher intensity (P<0.001) in
animals of the rotenone group compared with the control group
(P<0.001). The densitometry evaluation of MB-COMT did not
show any change in rotenone+PACAP group compared with control
animals (Fig. 5C). An interesting observation was the intense band
at around 36 kDa (Fig. 5A). This unspecific immunopositive band
decreased after rotenone treatment and it increased in the rotenone
+PACAP group compared with controls. We do not have direct
evidence about this protein in snail CNS but based on literature
data, we speculate that this crossreactive band might be a
sulfotransferase-like protein.
Effects of PACAP in a vertebrate model: 6-OHDA-induced
injury in rats
The ratio of DA content was determined from the SN 1, 3, 7, 9, 12,
14 and 16 days after 6-OHDA lesion. We observed that DA level
continuously declined at the beginning and reached a maximum
decrease on day 7 on the 6-OHDA-treated side compared with the
control side. Thereafter, no significant decrease was observed
(Fig. 6A). Therefore, for further experiments we sacrificed the
animals on day 7 after the operation to measure the DA and 5HT
levels of the SN. On the 7th postoperative day, the average DA level
was 4.24±0.73 µg/g tissue, while the average 5HT level was 3.53±
0.45 µg/g tissue in the SN of the control group (Fig. 6B). Following
6-OHDA treatment, levels of both DA and 5HT significantly
decreased compared with control animals: the DA content of the SN
was reduced to 48.71±4.65% (P<0.01) in the 6-OHDA-injected
animals. PACAP treatment counteracted the 6-OHDA effect since
DA content was reduced to only 73.93±4.31% (P<0.05) in the
PACAP-treated group (Fig. 6C). A significant difference was
observed between the 6-OHDA and 6-OHDA+PACAP groups
(P<0.01). PACAP treatment did not cause a similar change in 5HT
Fig. 1. HPLC-MS analysis of DA in SN of the rat. (A) Extracted ion chromatogram of DA at 1.95 min retention time in single ion monitoring (SIM) mode. (B) MS
spectrum of DA identified at 154.09 m/z parent ion protonated form [M+H]+. (C) Extracted ion chromatogram of DA fragment at 1.94 min retention time in MS/MS
mode. (D) MS/MS spectrum of DA identified at 137.06 m/z fragment ion protonated form [F+H]+ (219 fmol DA was injected). The calculated DA content was
3.87 µg/g SN tissue.
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levels: its content in the SN was reduced to 59.64±4.77% (P<0.05)
in 6-OHDA-treated animals and to 42.46±3.89% in 6-OHDA
+PACAP-treated rats (P<0.01). A significant difference was not
observed between the 6-OHDA and 6-OHDA+PACAP groups
(Fig. 6D).
Because PACAP had a protective effect on DA levels, in our
further experiments we focused on DA metabolism only. We
examined the possible changes in metabolic enzymes (MAO-B,
COMT) of DA using WB (Fig. 7). Bands of 55 kDa were detected
in control, 6-OHDA and 6-OHDA+PACAP groups by anti-MAO-
B antibody (Fig. 7A). The total protein content of crude extract of
SN was monitored using anti-β-actin (40 kDa) (Fig. 7A). The
metabolic enzyme of DA was examined by anti-COMT antibody.
Similar to invertebrate homogenates, the COMT was also
identified in 23 and 26 kDa bands in rat samples, representing
S-COMT and MB-COMT, respectively. The specific S-COMT
band showed higher intensity in the control group, and
significantly (P<0.001) decreased after 6-OHDA and 6-OHDA
+PACAP treatment (Fig. 7B). The 26 kDa band of MB-COMT,
however, showed different intensities between control, 6-OHDA
and 6-OHDA+PACAP groups. The highest intensity of the MB-
COMT was observed in the 6-OHDA group, while it was lower in
the other two groups. Densitometric evaluation showed that the
level of MB-COMT was significantly higher in the 6-OHDA
group compared with the control or 6-OHDA+PACAP groups
(P<0.001, Fig. 7C). Densitometry evaluation of the intensity of
the positive MAO-B signal did not reveal any changes between the
control and treated groups (Fig. 7D).
Short-term neurotoxin effect at the proteomic level
Changes at the proteomic level have been described in the serum,
SN and cerebrospinal fluid of PD patients and in the striatum of
toxin-induced parkinsonian rats (Licker et al., 2014; Lu et al., 2014;
Wang et al., 2013; Xiong et al., 2014). Therefore, we focused on the
toxin-induced changes of protein composition and the possible
protective effect of PACAP in the 6-OHDA model. Tissue
homogenates of SN isolated from left (treated) and right (control)
sides were separated by SDS-PAGE (n=3, Fig. S1). After
separation, significant differences were not detected in the quality
and quantity of total protein content on gel estimated by
densitometry evaluation. Therefore, in order to determine the
precise protein composition, the nanoLC-MS method was
performed. Quantitative analysis of PD-relevant proteins (PARK7,
myelin basic protein, D-dopachrome decarboxylase, thiosulfate
sulfurtransferase) was applied to the 95 different proteins identified
by database searching (Table S1). PARK7 protein, which belongs to
the ThiJ/Pfp1/DJ-1 superfamily, presented a marked difference after
treatment. This important chaperone protein was identified from the
∼20 kDa complex band, which also contained four other proteins
(phosphatidylethanolamine-binding protein, UMP-CMP kinase,
Ras-related protein Rab-6A, peroxiredoxin-1). PARK7 was the
only identified protein in the control group that had different
Fig. 2. HPLC-MS analysis of 5HT in SN of the rat. (A) Extracted ion chromatogram of 5HT at 3.89 min retention time in single ion monitoring
(SIM) mode. (B) MS spectrum of 5HT identified at 177.10 m/z parent ion protonated form [M+H]+. (C) Extracted ion chromatogram of 5HT fragment at 3.88 min
retention time in MS/MS mode. (D) MS/MS spectrum of 5HT identified at 160.08 m/z fragment ion protonated form [F+H]+ (143 fmol DA was injected). The
calculated 5HT content was 3.35 µg/g SN tissue.
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quantitative parameters, in contrast to other four proteins, which
were present in all groups at similar amounts independent of
treatment.
Finally, sandwich ELISA was used for the precise quantitative
determination of PARK7 protein in both toxin models. Fig. 8 shows
the PARK7 concentrations (μg/g) in snail and rat samples. In
the rotenone-induced snail model, the PARK7 concentration
Fig. 3. Survival, locomotion and feeding of snails after treatment with
PACAP, rotenone or rotenone+PACAP. (A) Survival in controls and after
treatment with PACAP, rotenone or rotenone+PACAP for 12 days. The total
number of animals was n=40 from 4 independent experiments in each group.
(B) Locomotor activity of snails of control (n=8), rotenone (n=8) and rotenone
+PACAP (n=8) groups. Mean distances covered during the 3 min test period by
snails are shown. One-way ANOVA: F(2)=13.99, P<0.001; post hoc test between
control and rotenone groups (P<0.001), control and rotenone+PACAP (P<0.01);
rotenone and rotenone+PACAP (P<0.05). (C) Feeding activity in snails of control
(n=8), rotenone (n=8) and rotenone+PACAP (n=8) groups.Meannumber of bites
counted during 2 min time window are shown. One-way ANOVA: F(2)=32.66,
P<0.001; post hoc test between control and rotenone (P<0.001), control and
rotenone+PACAP (P<0.01); rotenone and rotenone+PACAP groups (P<0.001)
(C). *P<0.05, **P<0.01, ***P<0.001between control and treatedgroups; #P<0.05,
##P<0.01, ###P<0.001 between rotenone and rotenone+PACAP groups.
Fig. 4. Monoamine concentrations in snails treated with rotenone and
rotenone+PACAP. (A) Monoamine concentration in snail control group in
µg/g tissue. (B) DA content as a percentage of control (n=30) in rotenone
(n=28) and rotenone+PACAP (n=30) groups. One-way ANOVA,
F(2,86)=39.03, P<0.001; post hoc test between control and rotenone groups
(P<0.001), control and rotenone+PACAP groups (P<0.001); rotenone and
rotenone+PACAP groups (P<0.05). (C) 5HT content as a percentage of
control (n=30) in rotenone (n=28) and rotenone+PACAP (n=30) groups.
One-way ANOVA, F(2,86)=18.41, P<0.001; post hoc test between control
and rotenone (P<0.001), control and rotenone+PACAP (P<0.001). Total
number of animals per group represents 3 independent experiments.
***P<0.001 between control and treated groups; #P<0.05 between rotenone
and rotenone+PACAP groups.
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significantly decreased (P<0.05) and could not be restored by
PACAP (P<0.05). In the 6-OHDA-induced model, the level of
PARK7 protein in the SN of the rat brain was significantly lower
compared with the control level (P<0.05). However, in PACAP-
pretreated rats, the PARK7 protein level was almost completely
restored (P<0.05).
DISCUSSION
Effect of toxins on behaviour, monoamines, enzymes and
PARK7 protein levels
The locomotion and rate of feeding activity were significantly
decreased in rotenone-treated snails compared with levels in
controls. The locomotion data correspond well to findings from
rat experiments where parkinsonian symptoms are induced by
6-OHDA and the animals show hypokinetic behavioural signs in
activity and asymmetrical measures (Tamas et al., 2006).
The DA and 5HT levels significantly decreased in both the
6-OHDA- and rotenone-induced models compared with the control
hemisphere or control group. The decrease of monoamine levels
correlated well with the degeneration of DAergic and 5HTergic
systems, which provide the background for development of
symptoms both in vertebrates and invertebrates (Duty and Jenner,
2011; Hely et al., 2005; Reglodi et al., 2004; Vehovszky et al.,
2007). Recently, it has been suggested that 5HT-mediated
neurotransmission is also altered in PD, and the involvement of
different 5HT receptor subtypes is hypothesized (Huot et al., 2011).
In invertebrates, 5HT, together with DA, are important
neurotransmitters in locomotor activity during cilia movement
(Katow et al., 2007; Sanderson et al., 1985) and 5HT is a main
transmitter of the feeding system (Balog et al., 2012; Krajcs et al.,
2014; Pirger et al., 2009). The chronic rotenone treatment decreased
brain DA and 5HT levels and led to the progressive and irreversible
decline in locomotion, feeding and in the life span of treated snails.
All these observations corresponded well with earlier results where
decreased feeding activity and DA level were observed on Lymnaea
as a result of rotenone treatment (Vehovszky et al., 2007).
In both models, the decreased locomotor activity and monoamine
levels correlated with quantitative changes of monoamine-
metabolizing enzymes (S-COMT, MB-COMT and MAO-B). Our
analysis was focused mainly on S-COMT and MB-COMT because
MAO-B could not be identified in the CNS of snails, and according
to the literature, it plays a minor role in eliminating monoamines
(Sloley, 2004). Furthermore, the MAO-B level did not change in the
rat 6-OHDA model either. Both COMT isoforms are widely
distributed in the brain. COMT appears mostly as S-COMT and
only a minor fraction is in the MB-COMT form. S-COMT is
thought to be mainly responsible for the elimination of biologically
active or toxic catechols, such as 6-OHDA (Mannisto and
Kaakkola, 1999; Mulcahy et al., 2012; Roth, 1992). In our
experiment, the S-COMT level significantly decreased in both the
vertebrate and invertebrate toxin models. It is suggested that
rotenone is metabolized mainly by oxidative processes like
demethylation and after rotenone demethylation, monomethyl
catechol and/or catechol forms will also appear in the brain.
Therefore, S-COMT could also be involved in the elimination of
rotenone metabolites (Haley, 1978). The decrease in S-COMT level
observed in both of our models could be explained by changes in the
original structure of S-COMT during enzymatic reaction (Mannisto
and Kaakkola, 1999). We suggest that because of the structural
changes of S-COMT, the anti-COMTantibody that we used may not
recognize the active isoform of S-COMT in theWB experiments. At
the same time, the MB-COMT enzyme plays a predominantly
distinct role. It has been found that MB-COMT is primarily
involved in the termination of DAergic synaptic neurotransmission
when there are physiologically relevant low concentrations of
Fig. 5. Analysis of DA metabolic enzymes in snail brain homogenates.
(A) Western blot with anti-COMT. The bottom panel shows detection of anti-β-
actin as a loading control. The top panel shows S- and MB-COMT localization
at ∼23 and 26 kDa. A non-linear adjustment (+0.5% level adjustment) was
applied to the MB-COMT band in rotenone group. Densitometry evaluations of
S-COMT (B) and MB-COMT (C) (n=3, calculated from independent WB
experiments). S-COMT: F(2)=135.80, P<0.001; post hoc test between control
and rotenone groups (P<0.001), control and rotenone+PACAP groups
(P<0.001). MB-COMT: F(2)=50.68,P<0.001; post hoc test between control and
rotenone (P<0.001), rotenone and rotenone+PACAP groups (P<0.001).
***P<0.001 between control and treated groups; ###P<0.001 between rotenone
and rotenone+PACAP groups.
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catecholamines (Mannisto and Kaakkola, 1999). In our WB
experiments the supernatant fraction was used; therefore, the
amount of MB-COMT was very low in contrast to S-COMT in
control situation in both models. Most MB-COMT activity resides
in the sediment after centrifugation (Jeffery and Roth, 1984; Roth,
1992). However, following toxin treatment, a significant increase of
the MB-COMT level was observed in both of our models. There are
two possibilities to explain our results. First, the increasing
concentration of MB-COMT could contribute to the decreasing
DA level. Second, the MB-COMT level might increase in nervous
tissues as a result of its release from disintegrating neurons.
Treatment with 6-OHDA and rotenone increase the level of reactive
oxygen species (ROS) in the cytoplasm, inducing cellular
disintegration (Tsushima et al., 2012). As well as COMT,
sulfotransferases also play key roles in the metabolism of
monoamine transmitters, including DA metabolism in both
invertebrates and vertebrates (Sloley, 2004). A few invertebrate
cytosolic sulfotransferases have been characterized from Nematoda
and Insecta with evolutionary conserved sequences (Hattori et al.,
2006, 2007, 2008; Pichu et al., 2011), but unfortunately, we do not
have sequence information about sulfotransferases in molluscs.
Drug-metabolizing sulfotransferase enzymes have a role in the
elimination of various environmental contaminants in mussels
(Oshima et al., 1994; Janer et al., 2005). The molecular mass of
sulfotransferases in ticks is reported to be the same as our most
intense nonspecific immunopositive band at ∼36 kDa in our WB
experiment. This band also shows a similar decrease in
concentration as observed in S-COMT after rotenone treatment.
Therefore, we speculate that this band might be a sulfotransferase-
like protein in the snail CNS. However, we do not have any
molecular or biochemical verification because the role of
sulfotransferase-like proteins has not been investigated in a toxin-
induced neurodegeneration model.
Ninety-five proteins were identified from 6-OHDA-treated rat SN
but of the PD-relevant proteins, a marked decrease was detected
only in the PARK7 chaperone protein level. PARK7 (DJ-1) belongs
to the peptidase C56 family of proteins and it has multiple functions
as an antioxidant, an oncogene and a molecular chaperone both in
vertebrates and invertebrates. Earlier studies established three
possible mechanisms by which PARK7 exerts neuroprotective
effects. First, it is able to stabilize the NRF2 protein, the antioxidant
transcriptional master regulator, thereby preventing apoptosis
induced by oxidative stress (Clements et al., 2006). Second, it
may inhibit the protein-associated splicing factor (PSF), which
normally has a transcriptional-silencing activity that stimulates
neuronal apoptosis (Xu et al., 2005). Third, the protein blocks
aggregation of mutant α-synuclein, preventing the formation of
Lewy bodies, which are an important hallmark of PD (Xu et al.,
2005). Based on these roles, it could be suggested that the protein
also plays a key role in neurotoxin-induced parkinsonian models.
Fig. 6. Monoamine concentrations in rat SN after treatment with 6-OHDA. (A) DA content of the SN 1, 3, 7, 9, 12, 14 and 16 days after operation (n=14). The y-
axis represents the ratio of DA levels in the hemispheres. Datawere calculated using the following formula: 100−(ct/cc×100), where ct=DA concentration of treated
SN (6-OHDA-injected, left hemisphere); cc=DA concentration of the control SN (right hemisphere). (B) Monoamine content (DA and 5HT) of control group
presented in µg/g tissue. (C,D) DA and 5HT content as a percentage of control (n=4) in 6-OHDA (n=6) and 6-OHDA+PACAP (n=7) groups. One-way ANOVA,
DA: F(2,18)=15.49, P<0.001; post hoc test between control and 6-OHDA groups (P<0.001), control and 6-OHDA+PACAP groups (P<0.05); 6-OHDA and 6-OHDA
+PACAP groups (P<0.01). 5HT: F(2,12)=12.87, P<0.001; post hoc test between control and 6-OHDA groups (P<0.05), control and 6-OHDA+PACAP groups
(P<0.01) (D). *P<0.05, **P<0.01, ***P<0.001 between control and treated groups; ##P<0.01 between rotenone and rotenone+PACAP groups.
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Although PARK7 has already been described in insects and
planarians (Lavara-Culebras and Paricio, 2007; Tsushima et al.,
2012), the presence of PARK7 or a PARK7-like protein in molluscs
is shown here for the first time. Because it is generally accepted that
PARK7 functions as an antioxidative agent, we examined its
concentration after neurotoxin treatment. PARK7 protein levels
were examined in both 6-OHDA-induced rat and rotenone-induced
snail models. Independent of the model species or the used toxins,
Fig. 7. Analysis of DA metabolic enzymes in rat SN after treatment with 6-OHDA. (A) S- and MB-COMT at 23 and 26 kDa in control, 6-OHDA and 6-OHDA
+PACAP groups are represented. Middle row shows the intensity of MAO-B. Anti-β-actin was used as an internal control (lower row). MAO-B (middle) and
β-actin (bottom) levels were similar in all groups. Changes in concentration of S-COMT (B), MB-COMT (C) and MAO-B (D) detected by densitometry were
identified at 23 kDa, 26 kDa and 55 kDa, respectively (n=3, calculated from independent WB experiments). S-COMT: F(2)=108.09; P<0.001; post hoc test
between control and 6-OHDA groups (P<0.001), control and 6-OHDA+PACAP groups (P<0.001). MB-COMT: F(2)=134.42; P<0.001; post hoc test between
control and 6-OHDA (P<0.001), 6-OHDA and 6-OHDA+PACAPgroups (P<0.001). ***P<0.001 between control and treated groups; ###P<0.001 between 6-OHDA
and 6-OHDA+PACAP groups.
Fig. 8. Comparison of PARK7 levels in toxin-treated snail CNS
and rat SN. Values were measured in control (n=3) and after
treatment with the different toxins (rotenone, n=5; 6-OHDA, n=4) and
toxin+PACAP-treated groups (n=5). Concentration of PARK7
protein is given in μg/g unit. Snails: F(2)=24.59, P<0.05; post hoc test
between control and rotenone groups (P<0.05), control and
rotenone+PACAP groups (P<0.05). Rat: F(2)=6.90,P<0.05; post hoc
test between control and 6-OHDA (P<0.05), 6-OHDA and 6-OHDA
+PACAP groups (P<0.05). *P<0.05 between control and treated
groups; #P<0.05 between toxin and toxin+PACAP groups.
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the level of PARK7 was significantly decreased. This decrease in
both models correlate well with data obtained in other vertebrate and
invertebrate studies (Miyama et al., 2011; Tsushima et al., 2012).
The observations suggest that PARK7 may have conserved
antioxidant and neuroprotective functions in animals and humans.
Protective effect of PACAP in toxin-treated animals
The effect of the neuroprotective agent PACAP on the insecticide
rotenone-induced survival rate of snails was tested. All rotenone-
treated snails died by day 12, in contrast to the 50% mortality
observed in the rotenone+PACAP-treated group, despite a slightly
higher initial mortality. PACAP is also known as a survival-
promoting peptide in vertebrate species, acting on divergent signal
transduction pathways. For example, PACAP plays a pivotal role in
immunity and inflammation, thereby prolonging the survival of
mice with ileitis (Heimesaat et al., 2014) and rats in kidney
ischemia-reperfusion models (Szakaly et al., 2008).
Earlier, we observed that PACAP-treated rats show significantly
better performance in behavioural tests in 6-OHDA-induced
neurodegenerative models. For example, they do not show signs
of hypoactivity and improvement of asymmetric symptoms is faster
than in control animals (Reglodi et al., 2004). PACAP was able to
prevent severe behavioural effects of rotenone in snails. The
spontaneous locomotor and sugar-induced feeding activities
significantly decreased in the behavioural test of both rotenone
and rotenone+PACAPgroups comparedwith control animals. These
results suggest that PACAP has a protective effect on locomotor and
feeding activities as well as in survival in both models.
Treatment of toxin-exposed animals with PACAP counteracted
the harmful effect of the toxin since it prevented the decrease of DA
levels in both models. This observation correlates well with our
earlier results, where PACAP treatment saved ∼50% of the DAergic
neurons after 6-OHDA-treatment in the SN pars compacta of rats
(Reglodi et al., 2004). Both toxins evoke a mitochondrial
dysfunction in DAergic neurons through a combination of
oxidative stress and injury to the mitochondrial respiratory system
(Duty and Jenner, 2011). 6-OHDA is known to act through complex
I or III inhibition while the target system of rotenone is complex
I. Both toxins increase the level of ROS in mitochondria,
causing an elevated cytochrome-c concentration in the cytoplasm.
Cytochrome-c, in turn, increases the level of caspase-9 and caspase-
3. This pathway could activate the apoptotic signal in neurons,
causing cell death and leading to a decreased DA level in the nervous
tissue. The PACAP-associated neuroprotection in 6-OHDA- and
rotenone-induced cell death is initiated by activation of adenylate
cyclase (AC) and protein kinase A (PKA), leading to a rapid
inhibition of caspase-3 activation in DAergic neurons (Falluel-
Morel et al., 2004). The inhibition of complex I and III leads to
reduced neuronal ATP production, which can be compensated by
PACAP through theAC system. In contrast toDA, PACAP treatment
could not compensate for the decrease in 5HT level in either the
vertebrate or the invertebrate model. The reason for this discrepancy
is unknown at the moment. Various studies have described either
increases or decreases of the 5HT level in models of PD, indicating
that the 6-OHDA-induced rat model is not the best for studying the
role of 5HT in PD (Mulcahy et al., 2012).
The level of S-COMT decreased significantly after application
of each toxin and could not be restored by PACAP. In contrast to
S-COMT, however, the increased MB-COMT level was
successfully restored by PACAP to the control levels in both toxin
groups. Based on these results, we conclude that PACAP has no
direct effect on metabolizing enzymes but it does appear to have a
general cell protective effect via MB-COMT. Consequently, more
neurons survive in the presence of PACAP, these surviving neurons
do not disintegrate and the level of MB-COMTwill be low, as in the
control.
A novel observation is that PACAP raised PARK7 chaperone
protein levels up to the control level in our rat parkinsonian model.
However, in the invertebrate toxin model, no effect of PACAP on
PARK7 was apparent, in contrast to the ameliorated behavioural
effects and actions on DA and related enzyme levels. We
hypothesize that this discrepancy might be due to the use of
different toxins in our models or possibly, different molecular
mechanisms of the protective effect of PACAP. Consequently, it is
suggested that 6-OHDA in rats and rotenone in snails could activate
different ROS-producing signal transduction pathways.
In summary, we conclude that the neuroprotective effect of
PACAP in different neurodegenerative animal models is well
correlated with neurotransmitter levels. The monoamine and
enzyme levels changed in parallel in 6-OHDA- and rotenone-
induced models; the only difference was in the PARK7 content. It is
believed that PACAP stimulates evolutionary conserved cellular
mechanisms in both models, leading to neuroprotection. In
conclusion, the rotenone and 6-OHDA rat and snail in vivo
parkinsonian models successfully present some clinical properties
of the disease and might offer an alternative way for studying the
molecular mechanisms of the protective effect of PACAP. Finally,
both 6-OHDA-induced vertebrate and rotenone-induced
invertebrate parkinsonian models could also be used to investigate
the neuroprotective effects of different polypeptides.
Possible therapeutic potential of PACAP
The cytoprotective effects of PACAP have been confirmed outside
the nervous system, including protective effects in the
gastrointestinal, cardiovascular and urogenital systems. Therefore,
possible future therapeutic approaches could be beneficial in several
pathological conditions. However, based on the widespread
occurrence of its receptors and the diverse actions of PACAP,
side-effects of such treatments should also be considered. For
example, as a vasodilator peptide, PACAP has been shown to lead to
temporary decreases in blood pressure and facial flushing (Li et al.,
2007; Seeliger et al., 2010), accompanied by edema and erythema
when applied in humans (Seeliger et al., 2010), although other
studies have found no alteration of blood pressure (Chiodera et al.,
1995). Also associated with its potent vasomotor actions, PACAP is
known to trigger migraine attacks in migraineurs (Schytz et al.,
2009; Tajti et al., 2015). One study reported an increased heart rate
after infusions in healthy volunteers (Birk et al., 2007). However,
despite these side-effects, intravenous infusions are well tolerated
(Li et al., 2007; Chiodera et al., 1995).
A lot of effort has been made to find analogues of PACAP
peptide and/or specific PAC1 receptor agonists that are more stable,
have long-lasting effects and preserve the protective functions
without the vasomotor side-effects (Doan et al., 2011; Vaudry
et al., 2010). A recent study has shown that a PACAP analogue
could be well tolerated, is stable against cleavage by dipeptidyl
peptidase and has strong neuroprotective effects (Lamine et al.,
2016). Infusion of the analogue led to falls of mean arterial
pressure in both PACAP- and Ac-[Phe(pI)(6), Nle(17)]PACAP(1-
27)-treated mice, and both the intensity and duration of the pressure
changes were reduced after injections of the analogue compared
with the native polypeptide. This and similar approaches could
serve as a basis for safe future therapeutic use of PACAP-induced
neuroprotective pathways.
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Comparison of the PD models
The use of vertebrate (mouse, rat, andmonkey) and invertebrate (snail,
insect) animals tomodel PDallows us to study the diseasemechanisms
aswell as to discover new drugs and possible treatments.Manymodels
successfully reproduce features of the disease and key pathological
properties of clinical PD within a shorter time (Cannon et al., 2009).
For example, the hydrophilic 6-OHDA (induces oxidative stress
triggered by ROS species via the vesicular DA and noradrenaline
transporters) induces progressive neuronal degeneration leading to
DAergic neuronal death and bradykinesia in less than 24 h or 1-
3 weeks depending on the site of application (Jeon et al., 1995; Sauer
and Oertel, 1994). The lipophilic rotenone (mitochondrial complex I
toxin) also induces a progressive neuronal degeneration of DAergic
neurons and bradykinesia in both vertebrates and invertebrates (Sherer
et al., 2003; Srivastava and Panda, 2007). The rotenone model
reproduces many features of PD, including the degeneration of
DAergic neurons and intracellular inclusions. The reproducibility of
this model is, however, difficult because of high mortality in both
vertebrates and invertebrates (Jagmag et al., 2016; Vehovszky et al.,
2007). Analysing behavioural data, monoamine levels and
metabolizing enzymes in the two different parkinsonian models, we
conclude that the vertebrate and invertebrate model are comparable,
since similar changes were observed in behaviour, monoamine and
enzyme levels. The only differencewas obtained in PARK7 in the two
models. Thus, themolecularmechanisms occurring in the PACAPand
PARK7 interaction could only be examined in the vertebrate model.
Therefore, the usefulness of the rotenone-induced parkinsonian model
could be questionable on the proteomic level in invertebrate species. It
could be avaluable parkinsonianmodel for investigating themolecular
mechanisms causing the change in monoamine and enzyme levels, as
well as for studying the mechanisms of neuroprotection. All toxin
models have advantages and disadvantages and may extend our
knowledge of the mechanisms of the disease and help us to discover
possible treatments (Jagmag et al., 2016). In addition to the rat 6-
OHDA parkinsonian model, here, we provide evidence for the
usefulness of a cheap invertebrate in vivo parkinsonian model to test
neuroprotective agents and explore their molecular mechanisms.
MATERIALS AND METHODS
Experimental animals
Snails
Pond snails (Lymnaea stagnalis) were bred at the Balaton Limnological
Institute, MTA-CER, Tihany. Animals were kept in separate large holding
tanks (30 litres) filled with filtered natural lakewater from Lake Balaton (18-
20°C). Snails were kept under a 12 h:12 h light:dark cycle and fed ad libitum
with lettuce and a vegetable-based fish food (Tetra Werke Company,
Germany). They were food deprived for 2 days before the beginning of the
behavioural and biochemical experiments. Experimental animals were
placed in separate tanks (10 animals per litre). All procedures on snails were
performed in accordance with the Hungarian Council on Animal Care
guidelines on the ethical use of animals (VE-I-001/01890-10/2013). Efforts
were made to minimize both suffering and number of animals used in the
experiments.
Rats
Wistar rats (weighing 200-250 g) were housed under standard laboratory
conditions. Animals were maintained under a 12 h:12 h light:dark cyclewith
free access to food and water (Reglodi et al., 2004). All procedures were
performed in accordance with the ethical guidelines approved by the
University of Pécs (BA02/2000-15024/2011).
Rotenone treatment in snails
We used a slightly modified published procedure (Vehovszky et al., 2007).
Snails not older than 3-4 months (young animals) were divided into four
groups (control, rotenone, rotenone+PACAP and PACAP). The control
group of snails was kept in filtered natural lake water (Lake Balaton) and
injected with 100 µl physiological solution. The rotenone group of snails
was kept in a tank containing 0.5 µM rotenone (dissolved in dimethyl
sulfoxide and added to the filtered natural lake water) and was injected with
100 µl physiological saline solution. The rotenone+PACAP group was kept
in a tank containing 0.5 µM rotenone solution and was injected with 100 µl
PACAP solution (100 µg in 1 ml physiological saline) for up to 12 days. In
order to test whether PACAP alone had any effect on the survival of the
animals, a fourth group was tested in the survival experiments. This PACAP
control group was kept in filtered lake water and was injected with 100 µl
PACAP solution (100 µg/ml). Since PACAP alone had no effect on
survival, we used only the other three groups for further experiments. The
whole survival experimental procedure was repeated four times (the total
number of animals was n=40/group). For monoamine studies, 30 animals/
group/experiment were used, whereas for behavioural tests (feeding and
locomotion), WB and ELISA studies, 10 animals/group/experiment were
used after 5 days of treatment. Snails were dissected after treatment and their
CNS, containing 5 paired and 1 unpaired ganglia, was removed for analysis.
Treatments were repeated daily in each group and water of both types was
also changed every day. In all cases, physiological saline or PACAP solution
was injected into the body cavity of snails using Hamilton syringes with fine
needles. Because there is no blood-brain barrier in the snail (Sattelle and
Lane, 1972), solution injected into the body cavity will have direct access to
the CNS. The injection procedure was performed using previously
published methods (Kemenes et al., 2002; Fulton et al., 2005).
6-OHDA treatment in rats
Rats were randomly divided into three groups (Reglodi et al., 2004). One
group of animals was given 2 μl physiological saline, followed by 2 μl 6-
OHDA (n=27) (Sigma) dissolved in physiological saline at a concentration
of 5 μg/μl containing 0.2% ascorbic acid into the left SN. PACAP-treated
animals (n=15) received 2 μg PACAP dissolved in 2 μl physiological saline
as pre-treatment, followed by 6-OHDA lesion of the SN. A physiological
saline-treated group served as a control (n=10). This group received only
physiological saline in the same volumes (2+2 μl) as 6-OHDA- and
PACAP-treated animals. Both injections were delivered into the left SN
(5.5 mm posterior, 2 mm left, and 8 mm ventral from bregma point) with a
Hamilton syringe over a period of 5 min, and the needle was left in place for
another 5 min. Injection procedures were applied to all groups on day 1. All
operations were performed under isoflurane anaesthesia.
Behaviour tests
Locomotion
Snails from control, rotenone and rotenone+PACAP groups were
individually placed in an experimental tank (10×20×3 cm; Salanki et al.,
2003) on day 5 of treatment. After acclimatization for 10 min, the
locomotion route of snails was marked continuously by a marker for
3 min. Digital photographs of each animal were taken using a Nikon D5100
camera after the test. Based on individual pictures, the traces made by a
single animal were measured (in cm) and analysed with Mousotron v.8.2
software (BlackSun; www.techspot.com/download).
Feeding
Feeding behaviour was followed by placing the snails individually into a
Petri dish filled with 20% sucrose solution, which evokes feeding activity,
i.e. rhythmic opening/closing movements of the mouth (Kemenes et al.,
1986). The feeding experiment was made on day 5 of treatment. After
acclimatization for 10 min, the evoked feeding rate was characterized by a
counter blind for the treatment for 2 min (the number of bites/2 min). Data
were processed in OriginPro8.
Determination of monoamines by HPLC-MS
The whole CNS of snails and SN region from the treated and non-treated
sides of rats were measured. For extraction of monoamines, acetonitrile was
applied containing 0.1% formic acid and 0.01 mass/vol% dithiothreitol. In
rats, the SN was dissected 1, 3, 7, 9, 12, 14 and 16 days after the operation,
and DA content was determined by HPLC-MS. Tissues were homogenized
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after addition of 200 µl extracting solution and were analysed with a high-
energy ultrasonicator UIS250V (Hielsher Ultrasound Technology, Teltow,
Germany) for 6×10 s, applying ice-cooling between cycles. Samples were
then vortex mixed and centrifuged (Heraeus Biofuge Pico, Thermo Fisher
Scientific, Waltham, MA, USA) at 8000 g for 5 min. Supernatants were
placed in a SpeedVac concentrator (Eppendorf Life Sciences, Hamburg,
Germany) at room temperature. The resulting samples were dissolved
fourfold in ultra-pure water containing 0.1% formic acid and loaded into
autosampler vials for HPLC-MS measurements (Sarvari et al., 2014).
Analyses were performed with a complex Ultimate 3000 (Dionex,
Sunnyvale, CA, USA) micro HPLC system equipped with a quaternary
pump, a degasser and a QExactive UHR spectrometer (Thermo Fisher
Scientific). Separations were performed on a Kinetex PFP column
(100 mm×2.1 mm i.d.; particle size, 2.6 µm; Phenomenex, Torrance, CA,
USA). The flow rate was 200 µl/min, the injection volume was 5 µl and the
temperature was kept at 4°C in the autosampler and 40°C in the column
compartment. Xcalibur (Thermo Fisher Scientific) software was used for
controlling the instrument, data acquisition and spectrum evaluations. A
gradient elution consisting of mobile phases A and B (A, 0.1% formic acid
in ultra-pure water; B, 0.1% formic acid in acetonitrile) was applied for the
chromatographic separation. The first 2 min were an isocratic period, the
mixing ratio was 97%:3% A:B eluents. The eluent composition was
changed for 60% B over the following 4 min. The column was washed with
60% B for 4 min and equilibrated to the initial conditions with 1 min
linear gradient and an isocratic period of 4 min. A QExactive mass
spectrometer equipped with a HESI source was used for mass detection. The
ionization source was operated with an endplate potential of 3 kV in the
positive ion mode. The following electrospray parameters were kept
constant during the analysis: drying gas (N2) flow, 10 l/min; auxiliary gas
flow, 2 l/min; sheath gas flow, 2 l/min; capillary temperature, 320°C; S-lens
RF level, 20%.
The minimum resolution of the mass spectrometer was 70,000. Filters of
SIM and MS2 modes were used for selective and sensitive detection of DA
and 5HT. The most intense precursor-to-fragment transitions were used for
quantitative analysis; for DA, 154.08→137.06 m/z; for 5HT,
177.10→160.08 m/z; 35 eV was applied as the normalized collision
energy (Sárvári et al., 2014).
Analysis of protein composition
To determine rat brain tissue protein composition a previously published
protocol of sample preparation and one-dimensional SDS-PAGE was
applied (Maasz et al., 2014). Briefly, brain samples were homogenized in
1 MTris-HCl, pH 8, containing 0.5 MEDTA, 0.7 M β-mercaptoethanol and
10% sodium dodecyl sulphate (SDS) and resolved on a 12% SDS-
polyacrylamide gel. All bands were excised from the gel with a razor blade,
digested with trypsin and analysed with Waters nanoACQUITY ultra-
performance liquid chromatography (Waters Corporation, Milford, MA,
USA) coupled to a nanoESI MS system. Aliquots (5 µl) of the samples were
injected and separated on a 1.7 µm BEH130 C18 analytical column
(75 µm×100 mm) using gradient elution at a flow rate of 350 nl/min. The
mobile phase was (A) aqueous formic acid solution (0.1%) with (B)
acetonitrilic formic acid solution (0.1%). Initial setting was 3% acetonitrile
(v/v), which was increased to 10% over 1 min, then increased to 40% in
15 min. The total run time was 30 min. The column temperature was set at
35°C. The temperature of the samples was 4°C. The nanoUPLC system was
connected to a Bruker Amazon SL ion trap MS instrument (Bruker
Daltonics, Bremen, Germany) coupled with a Captive Spray source. The
instrument was controlled using Compass v.1.3 software (Bruker Daltonics).
Themass spectrometer was operated in positive mode. The scanning mass to
charge rangewasm/z 100-3000 at a 1 Hz acquisition rate. Nitrogenwas used
as nebulizer gas, gas pressure was set to 0.6 bar, drying gas flow was 4 l/min
at 180°C and the capillary voltage was set to 3.8 kV. Each intensive peptide
peak was fragmented and the completed data were processed with the
DataAnalysis v.3.4 software (Bruker Daltonics). The identification of
proteins was carried out by searching in the limited rat taxonomy database of
the NCBI and SwissProt using Mascot v.2.4.1 (Matrix Science, London,
UK). The search parameters allowed for one missed cleavage site and
80 ppm mass error for the MS and 0.3 Da for the MS/MS mode.
Western blot assay
Proteins from rat SN and snail CNS were separated on a 12% SDS-
polyacrylamide gel and transferred to nitrocellulose membranes. After
blocking with 3% non-fat milk in Tris-buffered saline at 2 h, the membranes
were probed with antibodies recognizing: β-actin (Sigma, SAB5500001,
1:5000 dilution), COMT (Sigma, C6995, 1:1000) and MAO-B (Sigma,
AV43557, 1:1000 dilution) at 4°C overnight. Membranes were washed four
times in Tris-buffered saline (pH 7.5) containing 0.2% Tween (TBST) prior
to addition of goat anti-rabbit horseradish peroxidase-conjugated secondary
antibody (1:3000 dilution). Then samples were washed four times for 5 min
in TBST and the antibody-antigen complexes were visualized by
chemiluminescence method on conventional films.
Densitometry analysis was performed using Fiji ImageJ processing
software. Values were normalized relative to their corresponding β-actin
bands used as an internal standard. The analysis was repeated three times
with brain samples obtained from separate groups of animals.
Sandwich ELISA
The whole CNS of snails and the SN region from the treated sides of
rats were used for ELISA. Samples were homogenized in reagent
diluent (2.5 mg tissue/100 µl) then centrifuged (Heraeus Biofuge Pico,
Thermo Fisher Scientific) at 8000 g for 10 min at 4°C. The supernatants
were collected and transferred to ultra-high recovery Eppendorf tubes.
Special 96-well microplates (DJ-1/PARK7 DuoSet ELISA Kit; R&D
systems) were coated with 100 µl/well of capture antibody at 0.8 µg/ml in
PBS solution at room temperature overnight. The plates were washed three
times with buffer (0.05% Tween 20 in PBS, pH 7.2-7.4). Blocking was
performed with reagent diluent (300 µl/well, 1% BSA in PBS, pH 7.2-7.4)
and incubated at room temperature for 1 h. After washing, the DJ-1/PARK7
standards were added (0.313, 0.625, 1.25, 2.5, 5 ng/ml) to both snail CNS
and rat SN samples (100 µl/well). A control was prepared with capture and
detection antibody containing reagent diluent. Triplicates made on the plate
for each sample were incubated at room temperature for 2 h. The washing
protocol was repeated. Then 45 ng/ml detection antibody in reagent diluent
(100 µl/well) was added and incubated at room temperature for 2 h,
followed by an additional washing step. HRP (horseradish peroxidase)-
conjugated detection antibody was added at 1:40 in reagent diluent (100 µl/
well) and incubated at room temperature for 20 min in the dark. The bound
HRP conjugate was detected by adding 3,3′,5,5′-tetramethylbenzidine
(TMB) (Sigma, 100 µl/well) and incubated in the dark at room temperature
for 20 min. The presence of immune complexes was detected by
development of a blue colour and the enzymatic reaction was stopped by
adding 100 µl concentrated H2SO4. Finally, the optical density was analysed
with a microplate reader (PerkinElmer, Victor3 1420 multilabel counter) at
450 nm, and correction was made for absorbance at 550 nm due to
imperfections in the plate.
Statistics
Statistical analysis was carried out using SPSS v.20 (IBM, Budapest,
Hungary). Kaplan–Meier survival test with TaroneWare comparison was
made. Differences in the levels of DA and 5HT between the experimental
groups (snail: control, rotenone and rotenone+PACAP group; rat: control,
6-OHDA and 6-OHDA+PACAP group) were analysed. Normality of the
dataset was investigated using the Kolmogorov–Smirnov test, homogeneity of
variances between groupswas investigated using Levene statistics. Analysis of
variance was performed with one-way ANOVA with Scheffe and Tukey or
Tamhane post hoc tests. Differences were considered statistically significant at
P<0.05. Results in the figures are shown as mean±s.e.m.
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Fig.S1 – Proteomic profiling by one-dimensional gel electrophoresis. The proteins from left and right SN of one animal per each group 
were separated. Proteins were stained with Coomassie Brilliant Blue R-250. 
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Table S1 – Identified proteins of control and 6-OHDA rat SN samples. The first column shows the identification number (ID), the 
second column represents the NCBI codes, the third column is the name of identified protein. The last three columns represent the 
molecular weight (MW), Mascot Score and the sequence coverage (SC) in percentage. The highlighted rows represents the quantified 
PD relevant proteins. 
ID Accession Name 
MW 
[kDa] 
Mascot 
Score 
SC 
[%] 
1 HSP7C_RAT Heat shock cognate 71 kDa protein 70,8 813,6 36,2 
2 ACTG_RAT Actin, cytoplasmic 2  41,8 731,2 49,3 
3 CLH1_RAT Clathrin heavy chain 1 191,5 563,6 9,0 
4 ENOA_RAT Alpha-enolase  47,1 532,1 33,2 
5 KCRB_RAT Creatine kinase B-type 42,7 524,7 42,0 
6 G3P_RAT Glyceraldehyde-3-phosphate dehydrogenase  35,8 503,5 40,8 
7 HBA_RAT Hemoglobin subunit alpha-1/2  15,3 461,6 69,7 
8 PEBP1_RAT Phosphatidylethanolamine-binding protein 1 20,8 444,6 73,8 
9 1433G_RAT 14-3-3 protein gamma  28,3 423,1 33,2 
10 HBB1_RAT Hemoglobin subunit beta-1  16,0 416,3 57,1 
11 LDHB_RAT L-lactate dehydrogenase B chain  36,6 415,9 28,7 
12 HBA_RAT Hemoglobin subunit alpha-1/2  15,3 388,7 51,4 
13 LDHB_RAT L-lactate dehydrogenase B chain  36,6 378,1 26,3 
14 1433Z_RAT 14-3-3 protein zeta/delta  27,8 365,4 42,4 
15 HBB1_RAT Hemoglobin subunit beta-1 16,0 361,0 51,0 
16 1433B_RAT 14-3-3 protein beta/alpha  28,0 359,9 37,8 
17 HBB2_RAT Hemoglobin subunit beta-2  16,0 332,4 47,6 
18 TPIS_RAT Triosephosphate isomerase 26,8 323,4 36,9 
19 HBB2_RAT Hemoglobin subunit beta-2  16,0 315,5 46,9 
20 MDHM_RAT Malate dehydrogenase, mitochondrial  35,7 307,9 21,6 
21 1433Z_RAT 14-3-3 protein zeta/delta  27,8 299,9 41,6 
22 LDHA_RAT L-lactate dehydrogenase A chain  36,4 298,7 23,5 
23 PGAM1_RAT Phosphoglycerate mutase 1  28,8 289,6 46,5 
24 PRDX6_RAT Peroxiredoxin-6  24,8 286,5 33,5 
25 PARK7_RAT Protein DJ-1 20,0 278,4 54,0 
26 SOMA_RAT Somatotropin precursor (Growth hormone)  24,6 275,9 40,7 
27 HBA_RAT Hemoglobin subunit alpha-1/2  15,3 270,7 50,7 
28 DPYL2_RAT Dihydropyrimidinase-related protein 2 62,2 264,7 17,0 
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29 CH10_RAT 10 kDa heat shock protein, mitochondrial (Hsp10) (10 kDa chaperonin)  10,9 260,1 51,0 
30 1433F_RAT 14-3-3 protein eta  28,2 254,5 19,9 
31 PGK1_RAT Phosphoglycerate kinase 1  44,5 245,5 28,5 
32 G3P_RAT Glyceraldehyde-3-phosphate dehydrogenase  35,8 243,9 26,7 
33 1433B_RAT 14-3-3 protein beta/alpha  28,0 242,1 19,9 
34 UCHL1_RAT Ubiquitin carboxyl-terminal hydrolase isozyme L1  24,8 222,1 34,1 
35 LDHB_RAT L-lactate dehydrogenase B chain  36,6 209,2 17,1 
36 MDHC_RAT Malate dehydrogenase, cytoplasmic  36,5 189,1 13,5 
37 DHPR_RAT Dihydropteridine reductase  25,5 177,6 27,4 
38 ALDOA_RAT Fructose-bisphosphate aldolase A  39,3 172,3 14,8 
39 CRYM_RAT Mu-crystallin homolog  33,5 171,5 11,8 
40 MDHC_RAT Malate dehydrogenase, cytoplasmic  36,5 164,5 11,7 
41 MBP_RAT Myelin basic protein S (MBP S)  21,5 163,5 23,1 
42 HBA_RAT Hemoglobin subunit alpha-1/2 15,3 160,2 33,8 
43 PRDX2_RAT Peroxiredoxin-2  21,8 157,0 18,2 
44 GSTM1_RAT Glutathione S-transferase Mu 1  25,9 151,7 14,2 
45 KCY_RAT UMP-CMP kinase  22,2 149,0 22,4 
46 GSTM4_RAT Glutathione S-transferase Yb-3  25,7 148,9 14,2 
47 1433T_RAT 14-3-3 protein theta  27,8 148,0 22,9 
48 DOPD_RAT D-dopachrome decarboxylase  13,1 143,4 30,5 
49 RAB6A_RAT Ras-related protein Rab-6A  23,6 140,3 17,8 
50 DOPD_RAT D-dopachrome decarboxylase  13,1 138,9 17,8 
51 PRDX1_RAT Peroxiredoxin-1  22,1 138,2 22,6 
52 1433F_RAT 14-3-3 protein eta  28,2 137,7 15,0 
53 MBP_RAT Myelin basic protein S (MBP S)  21,5 134,9 16,9 
54 HBB1_RAT Hemoglobin subunit beta-1 16,0 128,8 34,7 
55 GDIR1_RAT Rho GDP-dissociation inhibitor 1 23,4 126,2 22,1 
56 PDXK_RAT Pyridoxal kinase 34,9 126,1 10,9 
57 GSTM4_RAT Glutathione S-transferase Yb-3 25,7 122,9 13,3 
58 CH10_RAT 10 kDa heat shock protein, mitochondrial (Hsp10) (10 kDa chaperonin)  10,9 121,3 13,7 
59 PDXK_RAT Pyridoxal kinase 34,9 120,0 9,3 
60 DOPD_RAT D-dopachrome decarboxylase  13,1 119,3 30,5 
61 SAHH_RAT Adenosylhomocysteinase  47,5 115,7 4,4 
62 ALBU_RAT Serum albumin precursor 68,7 114,9 6,9 
63 CALB2_RAT Calretinin  31,4 111,5 14,8 
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64 TBB2A_RAT Tubulin beta-2A chain  49,9 109,8 8,8 
65 MBP_RAT Myelin basic protein S (MBP S) 21,5 107,7 25,1 
66 NSF_RAT Vesicle-fusing ATPase  82,6 105,7 3,1 
67 MDHM_RAT Malate dehydrogenase, mitochondrial  35,7 99,6 7,1 
68 CALB1_RAT Calbindin (Vitamin D-dependent calcium-binding protein, avian-type) 30,0 98,5 7,3 
69 MBP_RAT Myelin basic protein S (MBP S)  21,5 95,6 11,3 
70 ERP29_RAT Endoplasmic reticulum resident protein 29  28,6 92,3 11,5 
71 HBB1_RAT Hemoglobin subunit beta-1  16,0 91,6 21,1 
72 CAH2_RAT Carbonic anhydrase 2  29,1 89,8 9,6 
73 MTPN_RAT Myotrophin (Protein V-1) (Granule cell differentiation protein)  12,9 89,0 14,4 
74 PRDX6_RAT Peroxiredoxin-6 24,8 88,9 18,3 
75 HPRT_RAT Hypoxanthine-guanine phosphoribosyltransferase 24,5 88,5 10,6 
76 ATPB_RAT ATP synthase subunit beta, mitochondrial  56,3 86,9 7,2 
77 ASGL1_RAT L-asparaginase  34,4 86,6 5,7 
78 NSF_RAT Vesicle-fusing ATPase  82,6 81,0 1,7 
79 IMPA1_RAT Inositol monophosphatase 30,5 78,6 4,3 
80 F10A1_RAT Hsc70-interacting protein (Hip) 41,3 77,4 9,5 
81 UCHL1_RAT Ubiquitin carboxyl-terminal hydrolase isozyme L1  24,8 74,1 7,2 
82 MTPN_RAT Myotrophin (Protein V-1) (Granule cell differentiation protein)  12,9 71,7 14,4 
83 NSF_RAT Vesicle-fusing ATPase  82,6 71,7 4,0 
84 LDHA_RAT L-lactate dehydrogenase A chain  36,4 71,2 3,0 
85 6PGL_RAT 6-phosphogluconolactonase  27,2 70,5 18,7 
86 THTR_RAT Thiosulfate sulfurtransferase  33,4 70,4 10,4 
87 TPIS_RAT Triosephosphate isomerase  26,8 69,9 5,2 
88 NSF_RAT Vesicle-fusing ATPase  82,6 68,3 1,7 
89 LGUL_RAT Lactoylglutathione lyase  20,8 67,6 11,4 
90 MIF_RAT Macrophage migration inhibitory factor  12,5 66,6 9,6 
91 UK114_RAT Ribonuclease UK114 14,3 64,5 19,0 
92 PRDX2_RAT Peroxiredoxin-2  21,8 64,3 14,1 
93 DOPD_RAT D-dopachrome decarboxylase  13,1 63,2 11,0 
94 MBP_RAT Myelin basic protein S (MBP S) 21,5 62,3 5,1 
95 DHPR_RAT Dihydropteridine reductase 25,5 59,5 6,6 
 
 
Disease Models & Mechanisms 10: doi:10.1242/dmm.027185: Supplementary information
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
S
up
pl
em
en
ta
ry
 in
fo
rm
at
io
n
